Esperoct Highly Effective as Prophylaxis for Hemophilia A, Study Suggests

Esperoct Highly Effective as Prophylaxis for Hemophilia A, Study Suggests

284576

Esperoct Highly Effective as Prophylaxis for Hemophilia A, Study Suggests

Severe hemophilia A patients using Esperoct (turoctocog alfa pegol) as a preventive treatment do well, with fewer bleeds or breakthrough bleeds, lower costs, and better life quality compared with other extended half-life (EHL) therapies, a modeling analysis suggested. The analysis was published in the journal ClinicoEconomics and Outcomes Research, in the study, “Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis…

You must be logged in to read/download the full post.